AU2006292871A1 - VHH for the diagnosis, prevention and treatment of diseases associated with protein aggregates - Google Patents

VHH for the diagnosis, prevention and treatment of diseases associated with protein aggregates Download PDF

Info

Publication number
AU2006292871A1
AU2006292871A1 AU2006292871A AU2006292871A AU2006292871A1 AU 2006292871 A1 AU2006292871 A1 AU 2006292871A1 AU 2006292871 A AU2006292871 A AU 2006292871A AU 2006292871 A AU2006292871 A AU 2006292871A AU 2006292871 A1 AU2006292871 A1 AU 2006292871A1
Authority
AU
Australia
Prior art keywords
vhh
antigen
protein
selection
aggregates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006292871A
Other languages
English (en)
Inventor
David Lutje Hulsik
Silvere Maria Van Der Maarel
Garritjan Boudewijn Van Ommen
Peter Verheesen
Cornelis Theodorus Verrips
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leids Universitair Medisch Centrum LUMC
Universiteit Utrecht Holding BV
Original Assignee
Leids Universitair Medisch Centrum LUMC
Universiteit Utrecht Holding BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leids Universitair Medisch Centrum LUMC, Universiteit Utrecht Holding BV filed Critical Leids Universitair Medisch Centrum LUMC
Publication of AU2006292871A1 publication Critical patent/AU2006292871A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C07K2317/82—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies functional in the cytoplasm, the inner aspect of the cell membrane, the nucleus or the mitochondria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2006292871A 2005-09-23 2006-09-25 VHH for the diagnosis, prevention and treatment of diseases associated with protein aggregates Abandoned AU2006292871A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05077180.7 2005-09-23
EP05077180 2005-09-23
PCT/NL2006/000475 WO2007035092A2 (en) 2005-09-23 2006-09-25 Vhh for the diagnosis, prevention and treatment of diseases associated with protein aggregates

Publications (1)

Publication Number Publication Date
AU2006292871A1 true AU2006292871A1 (en) 2007-03-29

Family

ID=35700351

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006292871A Abandoned AU2006292871A1 (en) 2005-09-23 2006-09-25 VHH for the diagnosis, prevention and treatment of diseases associated with protein aggregates

Country Status (6)

Country Link
US (1) US20100323905A1 (https=)
EP (1) EP1934611A2 (https=)
JP (1) JP2009508521A (https=)
AU (1) AU2006292871A1 (https=)
CA (1) CA2622968A1 (https=)
WO (1) WO2007035092A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006040153A2 (en) * 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
US20100092470A1 (en) * 2008-09-22 2010-04-15 Icb International, Inc. Antibodies, analogs and uses thereof
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
PT2491056T (pt) 2009-10-22 2021-10-26 Univ Of Twente Vhh para aplicação na reparação de tecidos, regeneração de órgãos, substituição de órgãos e engenharia de tecidos
UY33253A (es) * 2010-03-03 2011-09-30 Boehringer Ingelheim Int Polipéptidos de unión a a-beta
SG2014010482A (en) * 2011-08-17 2014-04-28 Glaxo Group Ltd Modified proteins and peptides
US10112987B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
US10112988B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
EP2873679A1 (en) * 2013-11-13 2015-05-20 F.Hoffmann-La Roche Ag Camelid single-domain antibody directed against amyloid bêta and methods for producing conjugates thereof
WO2018222587A1 (en) 2017-05-30 2018-12-06 The Regents Of The University Of California NANOBODIES AGAINST CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) INHIBITORY FACTOR (Cif)
JP7122672B2 (ja) * 2018-06-08 2022-08-22 パナソニックＩｐマネジメント株式会社 Ｖｈｈ抗体
CN109206519B (zh) * 2018-09-21 2021-12-03 成都阿帕克生物科技有限公司 一种抗尿素酶b亚单位的纳米抗体及核酸分子和应用
CA3174330A1 (en) * 2021-03-31 2022-09-30 Shugang YAO Binding agents targeting tumors and/or immune cells
CN121511255A (zh) * 2023-05-17 2026-02-10 奥德赛治疗股份有限公司 经修饰的单结构域抗体
TW202543670A (zh) * 2023-12-22 2025-11-16 比利時商艾伯霖克斯公司 用於核內投予之基於蛋白質的接合載劑

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9813276A (pt) * 1997-10-27 2000-08-22 Unilever Nv Proteìna multivalente de ligação de antìgeno, sequências de nucleotìdeos, vetor de expressão, célula hospedeira, processo para preparação de proteìna multivalente de ligação de antìgeno, e, uso da mesma
WO1999037681A2 (en) * 1998-01-26 1999-07-29 Unilever Plc Method for producing antibody fragments
AUPR546801A0 (en) * 2001-06-05 2001-06-28 Commonwealth Scientific And Industrial Research Organisation Recombinant antibodies
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
FR2846667B1 (fr) * 2002-11-06 2004-12-31 Pasteur Institut Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives
CA2505316C (en) * 2002-11-08 2014-08-05 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP1587838B1 (en) * 2003-01-10 2015-04-15 Ablynx N.V. Therapeutic polypeptides, homologues thereof, fragments thereof and their use in modulating platelet-mediated aggregation
WO2005052002A2 (en) * 2003-11-20 2005-06-09 Massachusetts Institute Of Technology Single-domain antibodies and uses thereof

Also Published As

Publication number Publication date
US20100323905A1 (en) 2010-12-23
JP2009508521A (ja) 2009-03-05
WO2007035092A2 (en) 2007-03-29
CA2622968A1 (en) 2007-03-29
WO2007035092A3 (en) 2007-07-12
EP1934611A2 (en) 2008-06-25

Similar Documents

Publication Publication Date Title
Verheesen et al. Reliable and controllable antibody fragment selections from Camelid non-immune libraries for target validation
AU2009324354B2 (en) Amino acid sequences directed against the Angiopoietin/Tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
US20210347855A1 (en) Synthetic Single Domain Antibody
US20100323905A1 (en) Vhh for the Diagnosis, Prevention and Treatment of Diseases Associated with Protein Aggregates
US9034325B2 (en) Amino acid sequences directed against multitarget scavenger receptors and polypeptides
EP2820046B1 (en) Cx3cr1-binding polypeptides
EP1420032A1 (en) Antibody recognizing gm1 ganglioside-bound amyloid beta-protein and dna encoding the antibody
AU2004293180A1 (en) Antibodies binding to a C-terminal fragment of Apolipoprotein E
EP1812062A2 (en) Anti-addl antibodies and uses thereof
CN117321076A (zh) 中和SARS-CoV-2的单结构域抗体
GB2585252A (en) Tau epitope and binding molecules
US11965038B2 (en) Pharmaceutical composition comprising antibody binding specifically to lysyl-tRNA synthetase N-terminus as effective ingredient for preventing or treating immune cell migration-related disease
US20240287501A1 (en) Means and Methods for Selection of Specific Binders
David et al. Identification and optimization of trans-species reactive TfR1-binding VHH as tools for drug delivery across the blood-brain barrier
CN110407942B (zh) 针对kn044的单域抗体
WO2025153033A1 (zh) 定向降解系统、其筛选方法及其用途
WO2023034842A2 (en) Monospecific and bispecific antibodies and antigen binding fragments thereof
HK40077734A (en) Cx3cr1-binding polypeptides
CN120173099A (zh) 一种抗pT181 Tau蛋白的单克隆抗体及其应用

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application